Published in Cancer Weekly, April 2nd, 2002
Such therapy has proved fruitful for increasing antitumor response and diminishing tumor size in mice, according to B. Carnemolla and a team of investigators at the National Institute for Cancer Research in Genoa, Italy.
The new fusion protein therapy takes advantage of angiogenic properties of extracellular matrix (ECM) components to shrink tumors. "Angiogenesis-associated ECM components represent appealing targets for the selective delivery of therapeutic molecules to...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.